Board of directors’ resolution on licensing of OBI-833, OBI-888 and OBI-999 in China (including Hong Kong and Macao)

Date of occurrence of the event: Sep 28, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): head office Reciprocal shareholding ratios: not applicable Cause of occurrence: To implement research strategy on a local level in China, OBI has accelerated to expand the potential indication for cancer cure products […]